Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins

Journal of Clinical Investigation

Volumn 110, Issue 4, 2002, Pages 499-504

  Auricchio, Alberto ^a   O'Connor, Erin ^a   Weiner, Daniel ^b   Gao, Guang Ping ^a   Hildinger, Markus ^a   Wang, Lili ^a   Calcedo, Roberto ^a   Wilson, James M ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9; CELL MARKER; ERYTHROPOIETIN; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CC10 GENE; CONTROLLED STUDY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TRANSFER; GENETIC CODE; HEMOPHILIA; MOUSE; NONHUMAN; POLYCYTHEMIA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SECRETION; VIRUS CAPSID;

EID: 0036677468     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215780     Document Type: Article

References (40)

1. The lung as a route for systemic delivery of therapeutic proteins and peptides
2. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo
3. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector
4. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo
5. Adeno-associated virus vectors for gene therapy: More pros than cons?
6. Gene therapy vectors based on adeno-associated virus type 1
7. Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells
8. Cloning of adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells
9. Cloning and characterization of adeno-associated virus type 5
10. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles
11. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2
12. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes
13. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors
14. Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry
15. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
16. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer
17. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer
18. cis-acting elements that confer lung epithelial cell expression of the CC10 gene
19. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column
20. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
21. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
22. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer
23. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo
24. Factors influencing recombinant adeno-associated virus production
25. A factor IX-deficient mouse model for hemophilia B gene therapy
26. Recombinant adeno-associated virus for muscle directed gene therapy
27. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs
28. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors
29. Gene transfer as an approach to treating hemophilia
30. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
31. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation
32. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
33. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
34. Persistent expression of canine factor IX in hemophilia B canines
35. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia
36. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
37. Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle
38. Gene therapy for the hemophilias
39. Haemophilia prophylaxis in young patients: A long-term follow-up
40. Successful readministration of adeno-associated virus vectors to the mouse Lung requires transient immunosuppression during the initial exposure